Buscar
Mesoblast Ltd
MESOAñadir a la lista de seguimiento
14.170USD
-0.380-2.61%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.87BCap. mercado
PérdidaP/E TTM
Más Datos de Mesoblast Ltd Compañía
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Información de Mesoblast Ltd
Símbolo de cotizaciónMESO
Nombre de la empresaMesoblast Ltd
Fecha de salida a bolsaDec 16, 2004
Director ejecutivoItescu (Silviu)
Número de empleados81
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 16
DirecciónL 38 55 Collins St
CiudadMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3000
Teléfono61396396036
Sitio Webhttps://www.mesoblast.com/
Símbolo de cotizaciónMESO
Fecha de salida a bolsaDec 16, 2004
Director ejecutivoItescu (Silviu)
Ejecutivos de Mesoblast Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+42.41%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Horst, Ph.D.
Mr. Justin Horst, Ph.D.
Head - Manufacturing
Head - Manufacturing
--
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+42.41%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Mesoblast Ltd?
Los cinco principales accionistas de Mesoblast Ltd son: Dr. Eric A. Rose, M.D.
¿Cuántas instituciones poseen acciones de Mesoblast Ltd (MESO)?
A fecha de 2026Q1, 144 instituciones poseen acciones de Mesoblast Ltd, con un valor de mercado combinado de aproximadamente 3.95M, lo que representa el 3.06% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -909190.00.